Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights trichotillomania's distinguishing "tonsure pattern" and nail-biting, emphasizing the need to differentiate it from other hair loss types due to differing treatments.

In this study, Trichophyton tonsurans and Microsporum canis were identified as the primary causes of tinea capitis, with terbinafine treatment showing the highest cure rate. Non-commercial kits surpassed real-time PCR commercial kits in specificity and sensitivity for diagnosis.

In this study, 37.5% of alopecia areata patients treated with tofacitinib were identified as super-responders, with significant predictors for this status being older age and no prior JAK inhibitor treatment, leading to faster and sustained hair regrowth.

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

This study presents a compilation of dermatological disorders that are descriptively compared to the "Navaratnas," or nine planetary gems from Vedic astrology, highlighting unique diagnostic terms and their clinical presentations to make dermatology more accessible and memorable for practitioners and patients.

This study reported that topical ω‐0‐acylceramide improved skin barrier function in Jack Russell Terriers with TGM1-deficient autosomal recessive congenital ichthyosis, normalizing skin pH and reducing transepidermal water loss.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study found that dermatoscopic features can distinguish between tinea capitis and alopecia areata in children, with tinea capitis commonly showing comma hairs and alopecia areata showing exclamation mark hairs.

This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.

This report highlights a case where dermoscopic observation of corkscrew hairs in a young woman led to the diagnosis of trichotillomania, emphasizing its role in distinguishing this psychiatric disorder from other forms of non-scarring alopecia and highlighting the importance of timely intervention.

This study proposed that the tiger tail phenomenon in trichothiodystrophy hair is caused by regular undulations of hair fibers, altering the optical properties seen under polarized light.

This source discusses the diagnosis and treatment of Tinea capitis in children, highlighting that Trichophyton tonsurans is the prevalent cause in the UK and that terbinafine is an effective treatment option.

In this study, introducing the rat OTC gene into spf-ash mice led to increased OTC activity and normalized hair growth and biochemical markers like urinary orotic acid and serum citrulline, partially correcting the symptoms of OTC deficiency.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.

This case report suggests that Trichostasis spinulosa should be considered in diagnosing treatment-resistant open comedone-like lesions and that skin surface biopsy might be an effective diagnostic method.

This case report describes two patients with trichothiodystrophy who exhibited a different pattern of hair protein composition changes, suggesting a subgroup of TTD characterized by partial loss of high-sulfur proteins without significant alteration in their amino acid composition.

In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.

This article discusses Hair-thread Tourniquet Syndrome in children, emphasizing the need for prompt examination and intervention to prevent severe complications, but reports no new clinical results.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This article highlights that tinea capitis in adults is often misdiagnosed, leading to treatment delays, and suggests fungal testing for those unresponsive to seborrheic dermatitis or psoriasis treatments.